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Abstract
In addition to genetic changes, the occurrence of epigenetic alterations is associated with accumulation of both genetic and
epigenetic events that promote the development and progression of human cancer. Previously, we reported a set of
candidate genes that comprise part of the emerging ‘‘cancer methylome’’. In the present study, we first tested 23 candidate
genes for promoter methylation in a small number of primary colon tumor tissues and controls. Based on these results, we
then examined the methylation frequency of Oncostatin M receptor-b (OSMR) in a larger number of tissue and stool DNA
samples collected from colon cancer patients and controls. We found that OSMR was frequently methylated in primary
colon cancer tissues (80%, 80/100), but not in normal tissues (4%, 4/100). Methylation of OSMR was also detected in stool
DNA from colorectal cancer patients (38%, 26/69) (cut-off in TaqMan-MSP, 4). Detection of other methylated markers in stool
DNA improved sensitivity with little effect on specificity. Promoter methylation mediated silencing of OSMR in cell lines, and
CRC cells with low OSMR expression were resistant to growth inhibition by Oncostatin M. Our data provide a biologic
rationale for silencing of OSMR in colon cancer progression and highlight a new therapeutic target in this disease. Moreover,
detection and quantification of OSMR promoter methylation in fecal DNA is a highly specific diagnostic biomarker for CRC.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers
among men and women and accounts for 10% of all new cancer
cases and cancer deaths each year [1]. The overall 5-year survival
rate from colon cancer has increased during the past 20 years
because of early detection from increased screening. In spite of
much progress, more advanced knowledge of the molecular
pathogenesis of CRC or key environmental/dietary factors in
CRC development is still needed. Moreover, finding potential
diagnostic markers and therapeutic targets for CRC will aid in the
early detection and treatment of colon cancer. Most CRCs arise
from adenomatous precursors, and accumulation of gain-of-
function mutations in proto-oncogenes and loss-of-function
mutations in tumor suppressor genes (TSGs) leads to progression
of adenomatous lesions to carcinoma [2,3,4].
In addition to genetic alterations involving mutations of
oncogenes and TSGs, carcinogenic progression from benign
neoplasm to adenocarcinoma can occur through epigenetic
changes in gene promoters [5]. Aberrant gene expression is a
characteristic of human cancers, and changes in DNA methylation
status can have profound effects on the expression of genes. TSGs
display both genetic and epigenetic inactivation in human tumors,
and the transcriptional silencing of TSGs has established
hypermethylation as a common mechanism for loss of TSG
function in human cancers [6] including colon cancer [7,8]. Thus,
knowledge of methylation patterns across the genome can help to
identify key TSGs inactivated during tumor formation [9,10,11].
Previously, we reported a set of candidate genes that comprise
part of the emerging ‘‘cancer methylome’’ by using a new
promoter structure algorithm and microarray data generated from
22 cancer cell lines derived form 5 major cancer types [12]. In this
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earlier study, we examined newly identified cancer-specific
methylated genes in a panel of 300 primary tumors representing
13 types of cancer. Based on the data, the number of known
cancer-specific methylated genes was increased by approximately
40%.
In the present study, we re-examined the methylation status of
cancer-specific methylated genes in a larger number of tissue and
stool DNA from colon cancer patients as well as patients without
cancer. We found that Oncostatin M receptor-b (OSMR) and b-1,4-
galactosyltransferase-1 (B4GALT) were highly methylated in primary
CRC tissues but rarely in corresponding normal adjacent mucosa
nor in non-malignant normal colon tissues. Methylation of these
genes was also detected in stool DNA from colon cancer patients,
but generally absent from non-cancer patients. Moreover, OSMR
and B4GALT mRNA expression in colon cancer tissues was
significantly down-regulated as compared to normal tissues.
Functional studies revealed a suppressive role for OSMR in colon
cancer progression. Hence, OSMR methylation is biologically
relevant and can be frequently detected in primary CRC tumors
and matched stool DNA.
Results
Microarray analysis in three human colon cancer cell lines
(HCT116, HT-29 and DLD1) identified 52 potential gene targets
based on reactivation after treatment with 5-aza-dC [12]. Of these
52 genes, sirtuin 2 (SIRT2) was counted twice in our candidate gene
list because it has two different gene identification numbers
(NM_012237 and NM_030593) in the NCBI database. In
addition, O6-methylguanine-DNA methyltransferase (MGMT) was pre-
viously reported to harbor cancer-specific promoter methylation in
multiple types of cancer including colon cancer [9], so we excluded
MGMT from our further analysis (52 -2 = 50). Secreted frizzled related
protein 4 (SFRP4) was previously reported to be methylated in colon
cancer [16,17] and was included as a positive control for gene
methylation in our study. Neurotrophin tyrosine kinase receptor type 2
(NTRK2) and urokinase type plasminogen activator (PLAU) were also
included because no reports on methylation of the two genes in
colon cancer have been published yet. We thus examined the
methylation status of a total of 50 genes by bisulfite-sequencing or
C-MSP in colon cancer cell lines (HCT116, DLD1, RKO, and
SW480) (Figure S1). As a result, we found 23 genes to be
methylated in more than one cell line (Table 1). Methylation in the
other 27 genes was not detected in any of the cell lines tested.
To identify genes harboring cancer-specific promoter methyl-
ation, we examined the methylation status of the 23 genes in five to
ten pairs of matched primary CRC (PT) and corresponding
normal colon (PN) tissues. Normal colon mucosa tissues from non-
cancer patients (NN) were also included to compare methylation
specificity between cancer and non-cancer patients. We excluded
genes that harbored methylation in NN with frequencies higher
than 30%. As a result, we found that 39-phosphoadenosine 59-
phosphosulfate synthase 2 (PAPSS2), c-tubulin gene 2 (TUBG2), NTRK2,
B4GALT1, and OSMR as well as SFRP4 harbored cancer-specific
methylation with high frequencies (.30%) (Table 2). All 6 of these
genes did not harbor methylation in all NN tested, and differences
in NN vs. PT and methylation vs. unmethylation cases were
statistically significant. Representative results of C-MSP, bisulfite-
sequencing, and COBRA in cell lines and tissues are shown in
Figure 1A and Figure S2.
To study promoter methylation of these 6 genes by TaqMan-
MSP real-time analysis, we designed primers and probes
specifically targeting the CpG islands of each gene (Figure S3).
We increased the sample numbers to over 25 pairs of primary
CRC (PT) and corresponding normal colon (PN) tissues, and to 13
normal colon mucosa tissues from non-cancer patients (NN). The
distribution of methylation values for each gene is shown in
Figure 1B. Due to heterogenous clonal patches known to expand
beyond the tumor borders, a low level of methylation in PN was
also commonly observed. The overall methylation values (Taq-
Man methylation values, TaqMeth V) are shown in Table 3.
B4GALT1 and OSMR harbored higher levels of overall methyla-
tion in PT than those in PN and NN, and the differences were
significant for both genes between PT and PN (P,0.001) and
between PT and NN (P,0.001). When methylation values were
compared within individual pairs of PN and PT samples,
significantly higher methylation levels of PAPSS2 TUBG2, NTRK2,
and SFRP4 were found in 60% (18/30), 50% (15/30), 30% (9/30),
and 36% (11/30), respectively, in PN than in corresponding tumor
samples (PT). Higher methylation levels of B4GALT1 in PN
samples was found only in 4 cases (13.3%, 4/30), and methylation
of OSMR was not found in any of the paired normals (0%, 0/25).
Methylation of the 6 genes in tissue showed highly discrimina-
tive receiver–operator characteristic (ROC) curve profiles, clearly
distinguishing CRC (PT) from normal colon mucosa (NN)
(P,0.001) (Figure S4A). AUROC (Area under ROC) was over
0.76 in all genes tested. In order to maximize sensitivity and
specificity, the optimal cut-offs for the 6 genes were calculated
from the ROC analysis (PT vs. NN) and are shown in Table 3. At
cut-offs set for optimal specificity of 90% or more, the sensitivity of
each gene in PT was over 70%. No cases of NN displayed
TaqMeth V over the optimal cut-offs for B4GALT1 and OSMR
(100% specificity). The sensitivities of B4GALT1 and OSMR were
83% (25/30) and 80% (20/25), respectively. These results indicate
that B4GALT1 and OSMR harbor cancer-specific methylation in
CRC with high frequency. Therefore, we focused on B4GALT1
and OSMR for further study.
We examined the methylation status of B4GALT1 and OSMR in
100 new pairs of CRC (PT) and corresponding normal (PN) tissues
by TaqMan-MSP analysis (Fig. 1C). The TaqMeth V in PT
ranged from 0 to 370.70 (median value 3.70) for B4GALT1 and
from 0 to 749.27 (median value 59.24) for OSMR. The value in PN
ranged from 0 to 9.70 (median value 0.26) for B4GALT1 and to
190.68 (median value 1.54) for OSMR. The overall methylation
levels of B4GALT1 and OSMR detected in PT (22.33648.69 for
B4GALT1 and 116.836151.52 for OSMR, mean6SD, n= 100)
were also significantly higher than those in PN (0.9061.37 for
B4GALT1 and 6.49621.52 for OSMR, mean6SD, n= 100)
(P,0.001). At the optimal cut-offs (values, 3.87 for B4GALT1
and 22.01 for OSMR) calculated from the ROC analysis (PT vs.
PN) (Figure S4B), the specificity of the two genes was over 96%.
The sensitivities of B4GALT1 and OSMR were 49% (49/100) and
80% (80/100), respectively. Taken together, B4GALT1 and OSMR
were frequently methylated in primary CRC tissues but displayed
absent or low levels of methylation in corresponding normal
tissues.
Next, we performed a blinded analysis of gene methylation
analysis in stool DNA collected from patients with or without
colon cancer. The clinical status of the patients was not revealed
until the analysis was completed. We also examined hypermethy-
lation of SFRP1 as a positive control for detection of gene
methylation in stool DNA [18]. The results of ROC analysis in the
stool DNA are shown in Figure 2. Table 4 shows the sensitivity/
specificity of each gene for colon cancer detected in stool DNA
samples. SFRP1 methylation was not detected in patients with
endoscopically normal colon (0%, 0/15), and was found in 55%
(11/20) of CRC patients, at the optimal cut-off value calculated
from the ROC analysis. Methylation of B4GALT1 and OSMR was
OSMR Methylation in CRC
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Table 1. Methylation profiles in CRC cell lines.
Refseq Name Method HCT116 DLD1 RKO SW480 % Frequency
NM_015049 ALS2CR3 SEQ U U U U U
NM_016201 AMOTL2 SEQ U U U U U
NM_001677 ATP1B1 SEQ U U U U U
NM_004323 BAG1 C-MSP U U n/d U U
NM_001497 B4GALT1 C-MSP M M M M 100 (4/4) M
NM_024834 C10orf119 SEQ M U U U 25 (1/4) M
NM_003876 C17orf35 SEQ U U U U U
NM_015578 C19orf13 SEQ U U U U U
NM_001757 CBR1 SEQ U U U U U
NM_004935 CDK5 SEQ U U U U U
NM_016129 COPS4 SEQ M n/d M n/d 100 (2/2) M
NM_006375 COVA1 SEQ U U U U U
NM_004078 CSRP1 SEQ M n/d M M 100 (3/3) M
NM_001349 DARS SEQ M U M U 50 (2/4) M
NM_018981 DNAJC10 SEQ U U n/d U U
NM_017946 FKBP14 SEQ M M M M 100 (4/4) M
NM_017739 FLJ20277 SEQ M M n/d M 100 (3/3) M
NM_024619 FN3KRP SEQ M M M M 100 (4/4) M
NM_014610 GANAB C-MSP U U U n/d U
NM_015234 GPR116 SEQ U U U U U
NM_000182 HADHA SEQ U U U U U
NM_004507 HUS1 SEQ M M M M 100 (4/4) M
NM_003597 KLF11 SEQ M M M M 100 (4/4) M
NM_018846 KLHL7 SEQ U U U U U
NM_146388 MRPL4 SEQ M M M M 100 (4/4) M
NM_002466 MYBL2 SEQ M M n/d M 100 (3/3) M
NM_053030 MYLK SEQ U M M M 75 (3/4) M
NM_015537 NELF SEQ U U U U U
NM_018092 NETO2 SEQ U U U U U
NM_006703 NUDT3 SEQ U U U U U
NM_003999 OSMR C-MSP U M M M 75 (3/4) M
NM_004670 PAPSS2 SEQ, C-MSP U U M M 50 (2/4) M
NM_006713 PC4 SEQ U U U U U
NM_002898 RBMS2 SEQ M M M M 100 (4/4) M
NM_015149 RGL1 C-MSP U U n/d U U
NM_004040 RHOB SEQ U U U n/d U
NM_005505 SECTM1 SEQ U U U M 25 (1/4) M
NM_003004 SCARB1 SEQ U U n/d U U
NM_012237 SIRT2 SEQ U U U U U
NM_016538 SIRT7 SEQ M M M M 100 (4/4) M
NM_015139 SLC35D1 SEQ U U U U U
NM_017767 SLC39A4 SEQ, C-MSP M M M M 100 (4/4) M
NM_004252 SLC9A3R1 SEQ, C-MSP M M M M 100 (4/4) M
NM_016614 TTRAP SEQ U U U U U
NM_016437 TUBG2 SEQ M M M M 100 (4/4) M
NM_003345 UBE2I SEQ U U U U U
NM_130839 UBE3A C-MSP U U U n/d U
NM_006180 NTRK2 C-MSP U U M n/d 33 (1/3) M
NM_002658 PLAU C-MSP U U U n/d U
NM_003014 SFRP4 C-MSP M M M n/d 100 (3/3) M
OSMR Methylation in CRC
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detected in 64% (9/14) and 80% (16/20) of stool DNA samples
from CRC patients, respectively. When methylation of SFRP1 and
OSMR was combined, the sensitivity was 60% (12/20), and the
specificity was 100% (0/15). Discrimination between patients
without cancer and CRC patients by SFRP1 or OSMR methylation
was statistically significant (P,0.01).
OSMR methylation was tested in a blinded fashion in one more
independent set of stool samples (no overlap with the samples in
Table 4). Stool DNA from healthy control subjects who had no
visual abnormalties in colonoscopy were included for this study.
The sensitivity of OSMR methylation in CRC patients was 38%
(26/69) and the specificity was 95% (77/81) (Table 5). The
difference between CRC patients and normal controls was
statistically highly significant (P,0.001). In addition, OSMR
methylation was detected in 56% (15/27) and 44% (8/18) stool
DNA samples from CRC stage II and III patients, respectively.
Moreover, 34 of 41 cases (83%) of fecal DNA from confounding
control patients without CRC were completely negative for OSMR
methylation. Other clinical parameters in confounding controls
such as diverticulosis, hemorrhoid, and polyps were not signifi-
Refseq Name Method HCT116 DLD1 RKO SW480 % Frequency
NM_002412 MGMT
When ‘‘methylation positive’’ was detected in any single cell line, it was considered as methylation (M) in cell lines.
No CpG islands in GPR116 and SLC39A4 were found within 1 kb upstream of the TSS.
C10orf119, SECTM1 and NTRK2 were only methylated in one cell line.
M, methylated; U, unmethylated. n/d, not determined.
doi:10.1371/journal.pone.0006555.t001
Table 1. Cont.
Table 2. Methylation profiles in colon tissues.
% Frequency Fisher’s exact
Genes Method PT PN NN ap value bp value
B4GALT1 C-MSP 100 (5/5) 0 (0/5) 0 (0/5) 0.008* 0.008*!
C10orf119 SEQ 0 (0/10) 0 (0/10) 0/10 n/a n/a
COPS4 SEQ 0 (0/5) 0 (0/5) 0 (0/5) n/a n/a
CSRP1 SEQ 50 (3/6) 90 (9/10) 100 (5/5) 0.118 0.182
DARS SEQ 22 (2/9) 40 (4/10) 40 (4/10) 0.628 0.628
FKBP14 SEQ 0 (0/5) 0 (0/5) 0 (0/4) n/a n/a
FN3KRP SEQ 100 (5/5) 100 (5/5) 100 (5/5) n/a n/a
FLJ20277 SEQ 100 (5/5) 100 (5/5) 100 (5/5) n/a n/a
HUS1 SEQ 22 (2/9) 0 (0/5) 0 (0/5) 0.505 0.505
KLF11 SEQ 100 (6/6) 100 (6/6) 100 (6/6) n/a n/a
MYBL2 SEQ 100 (9/9) 70 (7/10) 100 (5/5) 0.6 n/a
MRPL4 SEQ 100 (5/5) 100 (5/5) 100 (5/5) n/a n/a
MYLK SEQ 10 (1/10) 0 (0/10) 0 (0/10) 1.000 1.000
OSMR C-MSP 100 (5/5) 33 (1/3) 0 (0/5) 0.107 0.008*!
PAPSS2 SEQ, C-MSP 100 (5/5) 20 (1/5) 0 (0/5) 0.048* 0.008*!
RBMS2 SEQ 100 (10/10) 100 (7/7) 100 (10/10) n/a n/a
SECTM1 SEQ 0 (0/5) 0 (0/5) 0 (0/5) n/a n/a
SIRT7 SEQ 100 (4/4) 100 (5/5) 100 (3/3) n/a n/a
SLC39A4 SEQ, C-MSP 67 (6/9) 100 (6/6) 100 (10/10) 0.229 0.087
SLC9A3R1 C-MSP 100 (5/5) 100 (5/5) 100 (5/5) n/a n/a
TUBG2 SEQ, C-MSP 71 (5/7) 40 (2/5) 0 (0/5) 0.558 0.028*!
NTRK2 C-MSP 100 (5/5) 20 (1/5) 0 (0/5) 0.048* 0.008*!
SFRP4 C-MSP 100 (5/5) 0 (0/5) 0 (0/5) 0.008* 0.008*!
PN, corresponding normal colon mucosa from CRC patients; PT, CRC tissues; NN, colon normal epithelium from non-cancer patients.
P value was calculated from the Fisher’s exact test.
aPT vs. PN.
bPT vs. NN.
*P,0.05 was considered significant.
!Determination of genes harboring cancer-specific methylation was based on p,0.05 in PT vs. NN.
n/a, not assessed.
doi:10.1371/journal.pone.0006555.t002
OSMR Methylation in CRC
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Figure 1. Promoter methylation analysis. A, Methylation status of each gene was examined in CRC cell lines and tissues by C-MSP after PCR with
methylation-specific primers. PCR products were run on 4% agarose gels pre-stained with ethidium bromide. In vitro methylated, bisulfite-treated
human normal lymphocyte DNA (NL) was used as a positive control for PCR, and distilled water (DW) was used as a negative PCR control. b-actin was
used to confirm integrity of DNA. SLC39A4 and SLC9A3R1 were methylated both in cell lines and tissues, but GANAB, PLAU and UBE3A were not. The
other 5 genes were methylated in one of three cells lines tested, and only methylated in CRC tissues (PT). PN, paired normal colon tissues from colon
cancer patients; PT, paired CRC; NN, normal colon epithelium from non-cancer patients. C-MSP results of OSMR in CRC cell lines and tissues were
shown in a previous report [12]. B, Scatter plots of methylation values of six candidate genes in tissues and cell lines (CL). The overall methylation
values (TaqMan methylation values, TaqMeth V) and the optimal specificity/sensitivity at optimal cut-offs calculated from ROC analysis are shown in
Table 3. Arrows indicate the optimal cut-off values for each gene. No cases of NN displayed TaqMeth V over the optimal cut-offs for B4GALT1 and
OSMR. HEK293, a non-tumorigenic cell line, harbored a high level of B4GALT1 methylation (TaqMeth V, 101.12), but OSMR methylation was not
detected in the cell line (TaqMeth V, 0.00). *, Samples with a ratio equal to zero could not be plotted correctly on a log scale, so are presented here as
0.1. All assays were performed in duplicate format, and experiments were repeated twice. Data showed reproducible and concordant results in
triplicate. TaqMeth V is described in Materials and Methods. C, Quantitative methylation levels of B4GALT1 and OSMR in primary colon tissues. Scatter
plot of B4GALT1 and OSMR promoter methylation. Arrows indicate optimal cut-off values for each gene (3.877 for B4GALT1 and 22.01 for OSMR).
doi:10.1371/journal.pone.0006555.g001
OSMR Methylation in CRC
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cantly associated with OSMR methylation status in stool (data not
shown).
To examine the transcriptional levels of B4GALT1 and OSMR,
we performed RT-PCR or Real-time RT-PCR analysis (Fig. 3)
using cDNA prepared from CRC cell lines (HCT116, HT29,
DLD-1, RKO, and SW480) and a non-tumorigenic cell line,
HEK293. OSMR expression was observed only in the cells where
methylation of OSMR was not found (HCT116 and HEK293).
Increase of OSMR expression by 5-aza-dC treatment was
previously reported [12], indicating that expression of OSMR
correlates tightly with promoter methylation. Basal expression of
B4GALT1 was detected in all cell lines tested, and all of these cell
lines also harbored methylation of B4GALT1. However, B4GALT1
was further increased by 5-Aza-dC (Figure S5A), indicating that its
expression was at least partially suppressed by promoter
methylation.
We then performed Real-time RT-PCR in cDNA prepared
from tumor (PT) and corresponding normal tissues (PN) of five
individual colon cancer patients (matched cDNA). In 3 of 5
tumor cases, OSMR was significantly down-regulated (Fig. 3C,
left). The expression of B4GALT1 and OSMR in tumor was three
and four times lower than in normal tissue (NN), respectively
(Fig. 3B and C, right). By immunohistochemical staining of a
colon normal and cancer tissue microarray with an anti-OSMR
antibody, we detected strong expression of OSMR in all non-
malignant normal tissues (NN) and adjacent normal colon
mucosa (PN) from colon cancer patients (Fig. 4 and Table 6).
However, OSMR was barely detected in almost of all primary
tumors (PT) (weak expression in 4 of 10 cases). These results
suggest a specific decrease of OSMR mRNA and protein in colon
cancer development.
To investigate the role of DNA methylation in regulation of
OSMR expression, we transfected a pGL3-OSMR-Pro2-Luciferase
construct into three cell lines; a OSMR-negative cell line, SW480,
and two OSMR-positive cell lines, HCT116 and HEK293. The
construct was treated with or without SssI methylase before
transfection. Activity of the OSMR promoter was not detected in
SW480, but a high level of promoter activity was detected in
HCT116 and HEK293 cells (Fig. 5A). Induction of CpG
methylation with SssI methylase decreased the activity to minimal
levels.
Oncostatin M (OSM) is an interleukin-6 (IL-6)-type cytokine,
but more active than IL-6 in inhibiting the proliferation of
numerous solid tumor cell lines [19,20]. Recently, a correlation
of resistance to growth inhibition by OSM with specific loss of
the OSMR and Stat3 signaling was reported [15]. In order to
examine CRC cell resistance to growth inhibition by OSM, we
transiently transfected a siRNA pool targeting OSMR and a
non-targeting control siRNA into OSMR-expressing HCT116
cells, and performed a standard cell growth assay after treatment
of cells with a recombinant human OSM (rhOSM). We observed
significant growth inhibition by rhOSM in HCT116 cells, and
the inhibition was reversed by knock-down of OSMR (Fig. 5B,
left). A Stat3 inhibitor peptide (Stat3 Inh) that abrogated Stat3
activation (Fig. 5D) blocked the rhOSM-induced growth
inhibition in HCT116 cells (Fig. 5B, right). Consistently,
suppression of cell growth by rhOSM was not observed in
SW480 and DLD-1 cells with OSMR promoter methylation
(Fig. 5C). Interestingly, the inhibition of cell growth by 5-Aza-dC
treatment in SW480 and DLD-1 cells (*, P,0.05) was
significantly enhanced by the treatment of rhOSM (#,
P,0.05). Finally we observed that rhOSM activated Stat3
phosphorylation in HCT116 cells, regardless OSMR expression
levels (Fig. 5D, left). Expression of gp130 and LIFR mRNA was
observed in HCT116 cells (Fig. 5E), indicating that the
activation of Stat3 in HCT116 cells with very low OSMR
expression caused by siRNA transfection may be through
gp130/LIFR (type I OSM receptor)-mediated signaling. Erk
phosphorylation increased in HCT116 cells transfected with
siRNA targeting OSMR, and the basal level of phospho-Erk in
SW480 cells with OSMR methylation was higher than in
HCT116 cells (Fig. 5D). 5-Aza-dC partially decreased activated
Erk in SW480 cells, and rhOSM recovered basal Erk
phopshorylation in the presence of 5-Aza-dC. Thus, methylated
OSMR markedly decreased tumor-inhibiting signals from
rhOSM and key downstream signaling events.
Table 3. Sensitivity and specificity of gene methylation at optimal cut-off values for detection of colon cancer tissue.
TaqMeth V Optimal
Gene PT PN NN aP bP AUROC cP Cut-off % Specificity % Sensitivity dP
PAPSS2 19.466649.251 71.528681.698 0.03560.126 ,0.001* ,0.001* 0.766760.068 ,0.001 0.121 92.3 (12/13) 70.0 (21/30) ,0.001
TUBG2 5.83564.707 13.981610.476 0.00960.028 ,0.001* ,0.001* 0.966760.033 ,0.001 0.116 100 (13/13) 96.6 (29/30) ,0.001
NTRK2 9.647632.432 4.18565.220 0.27861.002 0.171 ,0.001* 0.866760.060 ,0.001 0.118 92.3 (12/13) 83.3 (25/30) ,0.001
SFRP4 26.595683.428 6.35669.786 0.37661.112 0.991 ,0.001* 0.939760.042 ,0.001 1.027 92.3 (12/13) 90.0 (27/30) ,0.001
B4GALT1 36.740671.673 1.38760.009 0.01560.056 ,0.001* ,0.001* 0.925660.034 ,0.001 0.317 100 (13/13) 83.3 (25/30) ,0.001
OSMR 25.584624.765 1.66661.742 0.02260.044 ,0.001* ,0.001* 0.884660.044 ,0.001 1.830 100 (13/13) 80.0 (20/25) ,0.001
TaqMeth V is expressed as mean6SD, and TaqMeth V is described in Materials and Methods.
P value was derived from Wilcoxon matched-pairs signed-ranks test.
aPT vs. PN.
*P,0.01 was considered significant.
P value was derived from the Wilcoxon-Mann-Whitney test.
bPT vs. NN.
AUROC is expressed as mean6SD, and optimal cut-off values were calculated from ROC analysis.
cP value in ROC analysis (PT vs. NN).
dP value in Fisher’s exact test (PT vs. NN).
Sensitivity, positive methylation/total tumor cases (PT); Specificity, negative methylation/total normal cases (NN).
% Methylation in PN was based on cut-offs from PT vs. NN.
Methylation level below the cut-offs was considered as unmethylated and over the cut-offs were as methylated.
PN, corresponding normal colon mucosa from CRC patients; PT, CRC tissues; NN, colon normal epithelium from non-cancer patients.
doi:10.1371/journal.pone.0006555.t003
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Discussion
Promoter methylation of key regulatory genes drives the cancer
process and in the right context can serve as a diagnostic marker and
a therapeutic target. Cancer-specific methylation serves as an
important biomarker for the early detection of cancer. Such markers
may supplement the cytopathological assessment of tissue biopsies or
potentially stand on their own as markers of disease in various bodily
fluids such as stool. To this end, the methylation frequency of genes
identified in primary tissues has important clinical implications.
Figure 2. ROC curve analysis in stool DNA. A blinded test was performed for gene methylation analysis in stool DNA collected from patients
with or without colon cancer. SFRP1 was included to compare methylation frequency of a known cancer-specific methylated gene. Sensitivity/
specificity based on optimal cut-offs calculated from ROC analysis is shown in Table 4.
doi:10.1371/journal.pone.0006555.g002
Table 4. Gene methylation detected in stool from colon cancer or non-cancer patients.
SFRP1 B4GALT1 OSMR SFRP1+OSMRd
Clinical features M (+) % P value M (+) % P value M (+) % P value M (+) % P value
Non-CRC/Non-ADa 0/15 0 e0.001* 2/10 20 e0.109 0/15 0 e0.004* 0/15 0 e,0.001*
CRCb 11/20 55 9/16 56 9/20 45 12/20 60
ADc 5/17 29 f0.185 n/a 2/16 13 f0.067 6/17 35 f0.191
Methylation positivity and negativity based on methylation level at cut-off values; 0 for SFRP1, 0 for B4GALT1 and 8.53 for OSMR. M(+), Methylation positive.
aPatients with endoscopically normal colon (diverticulosis, diarrhea, polyps or bloody stool).
bPatients with colorectal cancer.
cPatients with adenoma.
dSum of methylation from SFRP1 and OSMR. Sum of methylation positivity was calculated by counting cases determined to be methylation-positive for at least one
gene.
Sum of methylation negativity was calculated by counting cases determined to be methylation-negative for each gene.
Fisher’s exact test was performed in enormal vs.CRC, and fCRC vs. AD; *P,0.05 was considered significant. n/a, not assesed.
doi:10.1371/journal.pone.0006555.t004
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A number of genes are commonly hypermethylated in
colorectal cancer (CRC) including hMLH1, p16INK4a, p14ARF,
RAR-b, APC, MGMT, cyclin A1, CDX1, MYOD1, COX-2 and WT-1
[21,22,23]. However, genes methylated only in neoplastic tissues
with high frequency (over 40%) are rare. In this study, we
identified PAPSS2, TUBG2, NTRK2, B4GALT1 and OSMR [12,24]
as genes harboring cancer-specific promoter methylation in
human colorectal cancer. The theoretical sensitivity of each
methylated gene was over 70% and the specificities were over 90%
by TaqMan-MSP. The methylation frequency of each gene ranks
with only a few other genes methylated at high frequency in CRC
(Cyclin A1, CDX1, RAR-b, MYOD1, p15INK4b and COX-2) in a
cancer-specific manner [10].
Studies on B4GALT1 and OSMR have been reported in human
cancer. B4GALT1 is localized both in the Golgi complex and on the
cell surface [25], and is constitutively expressed in all tissues
including human colorectal mucosa [26] with the exception of the
brain [27]. The role of cell surface B4GALT1 in human cancer has
been reported; it is an estrogen-regulated gene in MCF-7 cells [28],
and its level was altered in highly metastatic lung cancer cells
compared with its less metastatic parental cells [29]. B4GALT1
promotes apoptosis by inhibiting the epidermal growth factor
receptor pathway [30] and increases cycloheximide-induced
apoptosis in human hepatocarcinoma cells [31]. Protein kinase B/
Akt inhibits apoptosis by down-regulation of B4GALT1 [25]. In
addition, enhanced epithelial cell proliferation of the skin and small
intestine and abnormal differentiation in intestinal villi were found
in B4GALT1-deficient mice [32], suggesting that B4GALT1 plays an
important and suppressive role in the proliferation of epithelial cells.
Thus, its inactivation by promoter methylation could lead to escape
of normal cellular controls and cancer progression.
OSMR is a receptor of Oncostatin M (OSM), an interleukin-6
(IL-6)-type cytokine identified as a potent suppressor of tumor cells.
Human OSM was originally described by its capacity to inhibit
melanoma proliferation in vitro [33,34], and its targets for growth
inhibition include lung carcinomas [35], ovarian carcinomas [36],
and breast tumors [37]. Resistance to growth inhibition by OSM in
metastatic melanoma cell lines correlated with a specific loss of
OSMR, in conjunction with a lower level of histone acetylation in
Table 5. OSMR methylation detected in stool samples.
Clinical features M (+) % eP value fP value
Controlsa 4/81 5
CRCb
Total 26/69 38 ,0.001*
Stagec I 2/18 11 0.299
II 15/27 56 ,0.001*
III 8/18 44 ,0.001*
IV 1/6 17 0.307
Confounding controlsd 7/41 17 0.031
Methylation positivity and negativity based on methylation level of OSMR at a
cut-off value 4.
M (+), Methylation positive.
aHealthy control subjects with no visual abnormalities in colonoscopy.
bPatients with colorectal cancer.
cI-IV, UICC stages.
dPatients without CRC (polyps, diverticulosis, and hemorrhoid)
eP values from Fisher’s exact test performed in Controls vs.CRC. *P,0.05,
significant.
fP value from Fisher’s exact test between total CRC vs.Confounding controls.
doi:10.1371/journal.pone.0006555.t005
Figure 3. Expression of B4GALT1 and OSMR. A, Expression of B4GALT1 and OSMR in cell lines was examined by RT-PCR analysis. Methylation of
B4GALT1 in the cell lines was examined by C-MSP or TaqMan-MSP. b-actin was used as a loading control. M, methylation; U, unmethylation. B and C,
Real-time RT-PCR was performed in five pairs (a – e) of normal (PN) and tumor cDNA prepared from CRC patients (PT) (left). Expression of B4GALT1 (B)
and OSMR (C) were also compared between patients with colon cancer (T) or without cancer (NN) (right). Relative expression (Fold) was calculated by
comparing the ratios of mRNA expression of B4GALT1 and OSMR to an internal control gene, GAPDH. Experiments were done in duplicate, and values
indicate means6SD. *, P,0.05. Experiments were done in duplicate, and values indicate means6SD. *, P,0.05.
doi:10.1371/journal.pone.0006555.g003
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the OSMR promoter region, suggesting that metastatic melanoma
cells could escape the growth control of OSM by the epigenetic
silencing of OSMR [15]. We discovered that promoter methylation
strongly correlates with OSMR expression and also found a
correlation of resistance to growth inhibition by OSM with loss of
OSMR in CRC cell lines. Thus, promoter methylation is a key
regulator of OSMR expression and all of these results support a
suppressive function for OSMR in human cancer.
Human OSM forms two types of heterodimeric signaling
complexes; gp130/leukemia inhibitory factor receptor (LIFR)
(type I OSM receptor complex) [39] and gp130/OSMR (type II
OSM receptor complex) [40]. gp130/LIFR can be activated by
LIF or OSM, but gp130/OSMR is activated by OSM only. The
type II receptor complex activates OSM-specific signaling
pathways via the JNK/SAPK and Stat1/Stat5 pathways, whereas
both type I and type II complexes activate Stat3 and Erk as
common signaling pathways in breast cancer cells [41]. In
addition, type I and type II receptor signaling may exhibit
antagonistic functions [42]. We found that OSM-mediated cell
growth inhibition was not observed in HCT116 cells with low
OSMR level despite Stat 3 phosphorylation. Since HCT116 cells
expressed gp130 and LIFR, rhOSM likely phosphorylates Stat3
through type I OSM receptor-mediated signaling, but in the
absence of gp130/OSMR this effect is not sufficient to mediate
sustained growth suppression [41]. In support of this notion,
rhOSM did not increase Stat3 phosphorylation in SW480 cells
which lack LIFR expression
From a clinical point of view, our results have potential
immediate diagnostic and therapeutic implications and deserve
further attention. In a blinded test performed in stool DNA from
CRC patients, B4GALT1 and OSMR methylation were successfully
detected with high frequency and thus have potential for identifying
individuals with colon cancer. When we tested an additional known
methylated gene, SFRP1 [18], in combination with OSMR the
sensitivity of the assay increased; 60% (12/20) of colon cancers were
detected in stool DNAwith perfect specificity (P,0.001). These data
suggest that promoter methylation of OSMR might serve as a true
indicator for the presence of colon cancer.
Therapeutically, both genes provide tantalizing clues for new
approaches in the treatment of CRC. Since B4GALT1 promotes
apoptosis by inhibiting the epidermal growth factor receptor
pathway [30], strategies to reverse promoter methylation and re-
Figure 4. Immunohistochemical analysis of OSMR in colon cancer tissue microarray with normal colon tissue controls. Strong
expression of OSMR was detected in all non-malignant normal tissues (NN) and adjacent normal colon mucosa (PN). In contrast, OSMR was rarely
detected in the neoplastic cells from colon cancer patients. Tumor grades are indicated.
doi:10.1371/journal.pone.0006555.g004
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express the gene might augment treatment with antibodies against
the EGFR receptor. Kras mutation is known to be a strong
indicator of resistance to EGFR targeted therapies [42,43]. It
would be interesting to know how many wild type K-ras colorectal
cancers harbor B4GALT1 methylation as a mechanism of EGFR
resistance. Demethylation of OSMR could also have therapeutic
impact by re-sensitizing cells to the inhibitory effects of OSM. This
approach could have an impact on multiple tumors types beyond
CRC since so many tumors have been found to be inhibited by
OSM. Finally, one could even envision a combined approach
where the addition of demethylation agents and OSM to anti-
EGFR antibodies could target colon cancer cells and greatly
diminish their chance of therapeutic escape.
Materials and Methods
Cell lines and tissues
Five CRC cell lines (HCT116, DLD1, RKO, SW480 and
HT29) were purchased from ATCC (Manassas, VA). CRC cell
lines were grown in 5X McCoy medium supplemented with 10%
fetal bovine serum. HEK293 cells were obtained from ATCC and
were grown in DMEM supplemented with 10% FBS. One
hundred pairs of gDNA from primary colorectal cancers (PT) and
matched normal adjacent colon mucosa (PN) were described
previously [13]. For statistical purposes, PT and PN were treated
as paired groups. Thirteen normal colon epithelial tissues (NN)
were obtained from patients without cancer from the Department
of Pathology, The Johns Hopkins University. Stool gDNA from
colon cancer patients, patients without cancer, and healthy control
subjects were kindly provided by OncoMethylome Sciences (Sart-
Tilman, Belgium). Written informed consent was obtained from
the patients who provided the colon epithelial tissues and the stool
gDNA, and this study was approved by the Institutional Review
Board of the Johns Hopkins University in US and Vrije
Universiteit Medisch Centrum in Belgium.
DNA purification from stool DNA and bisulfite treatment
Stool specimens were collected and immediately submerged
in stool stabilization buffer (Exact Sciences, MA) and stored at
room temperature until processing (within 72 hrs). For recovery
of human DNA, whole samples were homogenized in excess
volume (1:7) of stool homogenization buffer (Exact Sciences,
MA) and aliquoted in portions of 32 ml (the equivalent of 4 g of
stool). Each aliquot of stool samples were centrifuged and the
supernatants were incubated with RNase A for 1 hr at 37uC.
The DNA was then precipitated with sodium acetate (pH 5.2) -
isopropanol and washed with 70% ethanol. The DNA pellet
was subsequently re-suspended in 4 ml of 16TE (pH 7.4) and
proteinase K digested by the use of 400 ml of 10X buffer
(240 mM EDTA, 750 mM NaCl, pH 8.0), 400 ml of 10% SDS
and 20 ml of proteinase K (20 mg/ml), and samples were
incubated overnight at 48uC with constant shaking. After
centrifugation, 5 ml of phenol/chloroform/isoamylalcohol was
added and samples were incubated (with shaking at 225 rpm)
for 10 min at RT. After centrifugation again, the aqueous layer
was transferred into new tubes, and DNA was precipitated and
washed. Pellets were re-suspended in 2 ml of 16 TE solution
(pH 8.0). Bisulfite treatment of 1 mg of tissue gDNA was
performed to convert unmethylated cytosines to uracils for
methylation analysis. For stool DNA, an up-scaled DNA
modification step was applied to 32 mg of the obtained DNA,
using the EZ-96DNA Methylation Kit (Zymo Research, Los
Angeles, CA), according to the manufacturer’s protocol.
Bisulfite-treated DNA was concentrated using the Clean and
Concentrator Kit (Zymo Research) and eluted in 30 ml.
Sequencing and Combined Bisulfite Restriction Analysis
(COBRA)
All PCR reactions were done as described previously [14], and
the primer sequences of bisulfite-DNA amplification were
described previously [12]. PCR products were gel-extracted
(Qiagen, Valencia, CA) and sequenced with an internal primer
(F2) or forward primer (F1) using the ABI BigDye cycle sequencing
kit (Applied Biosystems, Foster City, CA). Searches for CpG
islands in each gene promoter were done by using the online
accessible software Methprimer. Bisulfite-sequencing primers were
designed at the CpG islands within 1 or 2 kb upstream of the
transcription start site (TSS). For COBRA, eluted DNA after gel
extraction was digested with BstU1 (New England Biolabs.,
Beverly, MA), which recognizes the CGCG sequence, for 3 hrs
at 60uC. Samples were loaded on a 10% acrylamide gel, stained
with 1X SYBR Green Gold (Molecular Probes, Eugene, Oregon),
and visualized under UV light.
Table 6. Immunohistochemical analysis of OSMR in colon
cancer tissue microarray with normal tissue controls.
Tissues Expression Tumor Grade
Colon Cancer
1 - III
2 - III
3 - III
4 + III
5 + II
6 - II
7 - II
8 - I
9 + I
10 + I
Non-malignant normal colon
1 ++
2 ++++
3 ++++
4 ++++
5 ++++
6 ++++
Cancer adjacent normal colon
1 ++++
2 ++++
3 ++++
4 ++++
5 ++++
6 ++++
7 ++++
8 ++++
Note, expression level is indicated as -, no or very faint expression.
+ mild expression
++ moderate expression.
+++ strong expression.
++++ very strong expression.
doi:10.1371/journal.pone.0006555.t006
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Figure 5. Cellular function of OSMR. A, Analysis of OSMR promoter activity by luciferase reporter assay in OSMR-positive (HCT116 and HEK293)
and - negative (SW480) cells. The promoter construct was pre-treated with or without SssI methylase for 8 hrs before transfection. The highest activity
was detected in HEK293 cells. Data are expressed as fold increase over pGL3-basic activity. Experiments were done in triplicate, and values indicate
means6SD. Mean values are presented. B, An siRNA pool targeting OSMR and non-targeting control were transiently transfected into HCT116, and
cells were treated with rhOSM (50 ng/ml) (left). HCT116 cells were treated with or without Stat3 inhibitor peptide (Stat3 Inh, 100 mM) acting as a
highly selective, potent blocker of Stat3 activation (right). Cell growth was determined by MTT assay. Data are expressed as absorbance at 570 nm.
Experiments were done in triplicate, and values indicate means6SD. *, P,0.05. C, 5-Aza-dC (5 mM) was pre-treated for 48 hrs in SW480 and DLD-1
cells, and then co-treated with rhOSM for 48 hrs. Cell growth was determined by MTT assay. *, 5-Aza-dC-treated cells compared to untreated control
(P,0.05); #, 5-Aza-dC/rhOSM- treated cells compared to 5-Aza-dC treatment alone (P,0.05). D, The phosphorylation of Stat3 and Erk in response to
rhOSM (50 ng/ml) was analyzed by Western blotting in HCT116 and SW480 cell lines. rhOSM increased phosphorylated Stat3 and Erk in HCT116 cells
but not in SW480 cells (which lack LIFR-see E below). Equal protein loading was monitored by total Stat3, Erk and b-actin evaluation in the samples.
Re-activation of OSMR by 5-Aza-dC treatment was determined on SW480 and DLD-1 cells by flow cytometry (Figure S6). E. Expression of LIFR and
gp130 was examined in CRC cell lines by RT-PCR. LIFR was expressed in HCT116 cells but silenced in most other CRC cell lines tested. gp130, the OSMR
heterodimer, was ubiquitously expressed in all cell lines tested. Promoter methylation status of these two latter genes was not examined.
doi:10.1371/journal.pone.0006555.g005
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The criteria to determine methylation in cell lines and
tissues
Bisulfite-sequencing was based on nucleotide sequences in
electropherograms. When only a cytosine or a thymidine peak
existed in a CpG, the sequence was ‘‘CG’’ (100% methylation) or
‘‘TG’’ (0% methylation). When both methylated and unmethy-
lated alleles were observed in a CpG sequence, it was considered
as ‘‘partially methylated’’ (M/U). When ‘‘partial methylated
CpG’’ was observed, a cytosine peak was compared to a thymidine
peak in the CpG. If a cytosine peak was similar to a thymidine
peak or dominant, the sequence in electropherograms was ‘‘NG’’
or ‘‘CG’’, indicating that over 50% methylated alleles existed.
When a thymidine peak was dominant, the sequence was ‘‘TG’’,
indicating less than 50% methylated alleles. Only ‘‘NG’’ and
‘‘CG’’ were considered as ‘‘methylated’’ in the CpG. When
‘‘methylated’’ CpG was found in more than 50% of total CpGs in
an amplified PCR product, it was considered as ‘‘methylation-
positive.’’ When any CRC cell line was ‘‘methylation-positive,’’ it
was classified as ‘‘methylation’’. Methylation in tissues was
determined when ‘‘methylation-positive’’ cases were observed in
over 30% of total tissues tested (over 30% frequency).
Conventional methylation-specific PCR (C-MSP)
Bisulfite-treated DNA was amplified with either methylation-
specific or unmethylation-specific primers for each gene. Primer
sequences are shown in Table S1. PCR reactions were performed
for 35 cycles of 95uC for 30 sec, 58uC for 30 sec, and 72uC for
30 sec. When clear PCR products amplified with methylation-
specific primers were detected, it was considered as ‘‘methylation-
positive.’’ Determination of overall methylation in cell lines and
tissues were the same as described above.
Quantitative methylation-specific PCR (TaqMan-MSP)
For quantitative methylation analysis, PCR primers were
designed to hybridize to the region of each gene that was
determined to be methylated in CRC cell lines by bisulfite-
sequencing or C-MSP, and a fluorescent probe was synthesized to
the amplified region of the DNA. Primer and probe sequences for
TaqMan-MSP are shown in Table S2. All oligonucleotide primer
pairs were purchased from Invitrogen (Carlsbad, CA), and the
TaqMan probe from VWR (West Chester, PA). All protocols for
TaqMan-MSP were performed as reported [14], and all reactions
were performed in duplicate. To ensure the specificity of the
TaqMan-MSP analysis, each 384-well PCR plate had wells that
contained bisulfite-converted DNA isolated from patient tissue
samples and wells that contained the following controls: in vitro
methylated normal lymphocyte DNA (NL, positive control), DNA
from normal colon mucosa in which each gene is not methylated
(negative control), and multiple water blanks (control for PCR
specificity). Lymphocyte DNA from a healthy individual was
methylated in vitro with excess SssI methyltransferase (New
England Biolabs Inc., Beverly, MA) to generate completely
methylated DNA, and serial dilutions (90–0.009 ng) of the DNA
were used to construct a calibration curve for each plate. All
samples were within the assay’s range of sensitivity and
reproducibility was based on amplification of an internal reference
standard (threshold cycle [CT] value for b-actin of#40). The
methylation ratio (TaqMan methylation value, TaqMeth V) was
defined as the quantity of fluorescence intensity derived from
promoter amplification of each gene divided by fluorescence
intensity from b-actin amplification, and multiplied by 100
(TUBG2, NTRK2, SFRP4, and OSMR) or 1000 (B4GALT1 and
PAPSS2). This ratio was used as a measure for the relative level of
methylated DNA in samples. The samples were categorized as
unmethylated or methylated based on optimal cut-offs from ROC
analysis.
Statistical Analysis
We used gene methylation levels (TaqMeth V) to construct
receiver operating characteristic (ROC) curves for the detection of
colon cancer. In the ROC analysis, tangent points where the
slopes of ROC curves were 1.00 have been selected as optimal cut-
off points to balance sensitivity and specificity. P value was derived
from Z value that was calculated from the equation of (AUROC-
0.5)/Std Err (standard error of AUROC). The cut-off values
determined from ROC curves were then applied to determine the
frequency of gene methylation. Samples with a methylation level
higher than cut-offs were designated as methylated, and samples
with a methylation level lower than cut-offs were designated as
unmethylated. All Statistical analyses in this study were conducted
using STATA Version 9 (STATA Inc., College Station, TX).
5-Aza-dC treatment, RT-PCR and Real-time RT-PCR
Cells were treated with 5 mM 5-aza-29-deoxycytidine (5-Aza-
dC) (Sigma, St. Louis, MO) every 24 hrs for 3 days. RNA was
extracted using Trizol (Invitrogen, Carlsbad, CA) and reverse-
transcribed with Superscript II reverse transcriptase (Invitrogen).
RT-PCR was performed by 30 cycles of 95uC for 1 min, 58uC for
1 min, and 72uC for 1 min. PCR products were gel-extracted and
sequenced to verify true expression of the genes. Five matched
normal and tumor cDNA (a-e) were purchased from Clontech
Laboratories, Inc. (Mountain View, CA), and cDNA panels of
human normal colon tissue (NN) and colon cancer tissue (T) were
purchased from BioChain Institute, Inc. (Hayward, CA). One ml of
each cDNA was used for real-time RT-PCR using QuantiFast
SYBR Green PCR Kit (Promega, Valencia, CA). Amplifications
were carried out in 384-well plates in a 7900 Sequence Detector
System (Perkin-Elmer Applied Biosystems, Norwalk, CT). Ther-
mal cycling was initiated with a first denaturation step at 95uC for
3 minutes, followed by 40 cycles of 95uC for 15 seconds, 58uC for
30 seconds, 72uC for 30 seconds. Expression of genes relative to
GAPDH was calculated based on the threshold cycle (Ct) as
22D(DCt), where DCt=Ct,GENE2Ct,GAPDH and D (DCt) =
DCt,N2DCt,T (N, matched normal tissue cDNA; T, tumor tissue
cDNA; NN, normal tissue cDNA from patients without cancer).
Primer sequences are shown in Table S3.
Immunohistochemistry
Tissue microarrays were performed with sections (5 mm) of
colon cancer tissues, adjacent tissues 1.5 cm away from tumor,
and non-malignant normal colon tissues which were purchased
from US Biomax, Inc. (Rockville, MD). The tissues were
deparaffinized and incubated with anti-OSMR rabbit polyclonal
antibody (1:100 dilution) (Santa Cruz Biotechnology, Santa Cruz,
CA) at 4uC overnight. They were then incubated in broad
spectrum secondary antibody purchased from DAKO (Carpin-
teria, CA) for 30 min. After washing the slides in PBS, tissue
sections were stained with freshly prepared DAB chromogen
solution (DAKO). We treated tissues with streptavidin and biotin
(Invitrogen) for 20 min each to block endogenous biotin levels.
Sections were counterstained in Mayer’s Hematoxyline.
Luciferase reporter assay
The pGL3-OSMR-Pro2-Luciferase construct designed to con-
tain a CpG island (2693 to+229 relative to the TSS) was kindly
provided by Dr. Frederic Blanchard (Universite´ de Nantes,
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France) [15], and transfected into HEK293, HCT116 and SW480
cells at a density of 16105/well in a 24-well plate. For each well,
100 ng of the pGL3-OSMR-Pro2-Luciferase constructs was co-
transfected with 10 ng of internal control reporter pSV-Renilla
(Promega) using Fugene-6 (Roche, Basel, Switzerland) in accor-
dance with the manufacturer’s instructions. After 48 hrs, the
luciferase assay was performed using a Dual luciferase assay kit
(Promega) and a single-sample luminometer (PerkinElmer,
Waltham, MA). The luciferase activity was normalized by pSV-
Renilla activity, and the pGL3–basic vector was used as a control.
The pGL3-OSMR-Pro2-Luciferase construct and the pGL3–basic
vector were methylated in vitro using SssI (CpG) methylase as
recommended by the manufacturer’s instructions (New England
Biolabs, Beverly, MA). After DNA isolation, equal amounts
(100 ng) of the methylated or unmethylated luciferase constructs
were transfected into cells. Each experiment was performed twice,
each in triplicate.
Knockdown of OSMR and cell growth assay
A siRNA pool targeting OSMR and non-targeting control were
purchased from Dharmacon (Chicago, IL). Fifty nM of each
siRNA were transiently transfected to HCT116 using Lipofecta-
mineRNAiMax transfection reagent (Invitrogen) in OPTI-MEM.
After 24 hrs, cells were incubated in complete growth medium.
Initial cell seeding density was 56103/well in 24 well plates, and
the antiproliferative activity of rhOSM (50 ng/ml) (R & D systems,
Minneapolis, MN) was measured by the MTT assay. After 4 hr
incubation in serum-deprived condition, cells were treated with
rhOSM in 0.1% serum medium, and incubated for 2, 3, or 4 days
as indicated. Stat3 inhibitor peptide (100 mM, cell permeable)
purchased from Calbiochem (La Jolla, CA) was pre-treated for
1 hr and 30 min during serum starvation, and co-treated with
rhOSM for 72 hrs. 5-Aza-dC (5 mM) (Sigma, St. Louis, MO) was
pre-treated for 48 hrs, and co-treated with rhOSM.
Western blot analyses
After pre-treatment with 5-Aza-dC or Stat3 inhibitor, rhOSM
was treated in serum-free condition for 30 min, and whole cell
lysates were extracted in RIPA buffer, separated on 4–12%
gradient SDS-PAGE, and transferred to nitrocellulose. The blots
were incubated with either anti-OSMR, anti-phospho-Erk
(Tyr204), anti-phospho-Stat3 (Tyr705), anti-Erk, anti-Stat3, or
anti-b-actin antibody for 2 hrs at room temperature or 4 uC
overnight. After antibody washing, the blots were incubated with
their respective secondary antibody and detected with enhanced
chemiluminescence reagents (Amersham, Pittsburgh, PA) accord-
ing to the supplier’s protocol. All antibodies were purchased from
Cell Signaling Technology (Danvers, MA) except anti-OSMR and
anti-phospho-Erk (Tyr204) (Santa Cruz Biotechnology) and anti-b-
actin (Sigma) antibodies.
Flow cytometry analysis
Cell surface expression of OSMR on SW480 and DLD-1 cells
was detected using an anti-OSMR-phycoethryin (PE) conjugated
antibody (Santa Cruz Biotechnology). Mouse IgG-PE antibody
was used as an isotype control (Santa Cruz Biotechnology). Cell-
associated fluorescence was acquired by a FACScaliber fluorocyt-
ometer (BD Biosciences) and analyzed using Cell-Quest software.
Supporting Information
Figure S1 Fifty-two candidate genes thought to be relevant to
colon cancer by the new promoter structure algorithm were
identified after initial analysis. A total of 50 genes were analyzed
for detection of promoter methylation in CRC cell lines. UnM,
unmethylated gene group; M, methylated gene group.
Found at: doi:10.1371/journal.pone.0006555.s001 (0.11 MB PPT)
Figure S2 Representative results of bisulfite sequencing in CRC
cell lines and tissues (A). Genomic and bisulfite-treated genomic
DNA sequences are indicated. *, Cytosine that was not protected
by methylation was thus converted to Thymidine after bisulfite
treatment. Underlined CGs, methylated CpGs that were main-
tained after bisulfite treatment. Primer sequences for bisulfite-
sequencing were described previously (12). B, Promoter methyl-
ation of TUBG2 in cell lines was examined by C-MSP (a), and in
tissues was examined by COBRA after digestion of gel-extracted
PCR products with BstU1 (b). Samples were loaded on a 10%
acrylamide gel, stained with 1 X SYBR Green Gold (Invitrogen)
and visualized under UV light. Multiple cleaved bands by BstU1
digestion were detected in PT samples (1–5) after gel separation,
indicating the continued presence of protected CGCG sequences
as a result of methylation, whereas no BstUI cleavage was found in
any NN samples (6–10). Due to tissue heterogeneity, methylated
and unmethylated alleles co-exist in PT samples so that uncleaved
bands can be seen. Mock digestion (without BstU1) of PT samples
resulted in the same uncleaved band as BstU1 digestion of the
normal colon mucosa PCR product. PT, paired CRC; NN,
normal colon epithelium from non-cancer patients. (c), Represen-
tative bisulfite-sequencing results of the TUBG2 promoter. Only
methylated alleles were detected in all cell lines tested whereas
methylated/unmethylated alleles coexisted in PT and PN tissues.
The criteria to determine methylation in cell lines and tissues are
described in Materials and Methods.
Found at: doi:10.1371/journal.pone.0006555.s002 (1.48 MB PPT)
Figure S3 CpG islands 1 Kb upstream of the transcription start
site (TSS) in the candidate gene promoters. Graphics depicting
CpG islands (gray) were taken from Methprimer software.
NTRK2 and OSMR had two CpG islands and the other four
genes had one CpG island within 1 Kb upstream of the TSS.
Promoter regions analyzed in this study partially or completely
covered the CpG islands indicated. Methylation for PAPSS2,
TUBG2 and OSMR was examined at two different promoter
regions. The location of the TSS is shown in each gene promoter.
Primer sites for bisulfite-DNA amplification and C-MSP and
TaqMan-MSP are indicated as Bi-F and Bi-R, and mF and mR,
respectively. Probes for TaqMan-MSP analysis are indicated as P.
Primers for C-MSP (mF-mR) were used for TapMan-MSP
analysis. F, forward; R, reverse.
Found at: doi:10.1371/journal.pone.0006555.s003 (0.43 MB PPT)
Figure S4 A, ROC curve analysis of 6 candidate genes (PT vs.
NN). Area under the ROC (AUROC) conveys the accuracy in
distinguishing NN from PT in terms of sensitivity and specificity.
Solid line, genes analyzed; dashed line, no discrimination. B, ROC
curve analysis (PT vs. PN) of B4GALT1 (left) and OSMR (right) in
100 pairs of CRC (PT) and corresponding normal (PN) tissues.
Found at: doi:10.1371/journal.pone.0006555.s004 (0.38 MB PPT)
Figure S5 Expression of B4GALT1 and OSMR. A, B4GALT1
was reactivated by the 5-Aza-dC treatment (Aza), and OSMR
reactivation by 5-Aza-dC was previously reported [12]. Fold
induction was calculated by comparing the ratios of B4GALT1 or
OSMR mRNA to GAPDH (an internal control) before and after
treatment. Fold induction ranged from 1.7 to 4.4 for B4GALT1
and from 5.2 (HCT116) to 2,868 (DLD-1) for OSMR (12).
Expression of the B4GALT1 (B) and the OSMR (C) in CRC cell
lines was quantitatively compared by real-time RT-PCR. The
lowest expression of OSMR was detected in SW480 cell line.
OSMR Methylation in CRC
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Experiments were done in duplicate, and values indicate
means6SD. *, P,0.05.
Found at: doi:10.1371/journal.pone.0006555.s005 (0.88 MB PPT)
Figure S6 Re-activation of OSMR by 5-Aza-dC treatment. Cell
surface expression of OSMR was determined on SW480 and
DLD-1 cells by flow cytometry. Values shown as insets correspond
to the mean of fluorescent intensity ratios between cells with or
without 5-Aza-dC treatment (3 days). Mouse IgG-PE antibody was
used as an isotype control (data not shown).
Found at: doi:10.1371/journal.pone.0006555.s006 (0.14 MB PPT)
Table S1 mF, methylation-specific forward; mR, methylation-
specific reverse; uF, unmethylation-specific forward; uR, un-
methylation-specific reverse. aPrimers used for detection of
methylatoin in cell lines; bPimers in cell lines and tissues.
Found at: doi:10.1371/journal.pone.0006555.s007 (0.19 MB PPT)
Table S2
Found at: doi:10.1371/journal.pone.0006555.s008 (0.17 MB PPT)
Table S3 Primers for RT-PCR are the same as for Real-Time
RT-PCR.
Found at: doi:10.1371/journal.pone.0006555.s009 (0.11 MB PPT)
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